MedTrace Logo

Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis

NCT01329042 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-04-05

No results posted yet for this study

Summary

Extracorporeal shock wave lithotripsy (ESWL) and Percutaneous nephrolithotomy (PCNL) become the therapy of choice for renal stone. Although providing good results, stone recurrence is usually found as the therapies do not change the underlying metabolic abnormality. Among the metabolic disorders, hypocitraturia is an important risk factor for calcium nephrolithiasis. This study evaluate the preventive effects of potassium sodium citrate on stone recurrence as well as stone growth post ESWL or PCNL, in patients with calcium-containing stones.

Conditions

  • Kidney Calculi

Interventions

DRUG

Potassium-sodium citrate

The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment

Sponsors & Collaborators

  • Chiang Mai University

    collaborator OTHER

  • Prince Songkla University

    collaborator UNKNOWN

  • Chulalongkorn University

    collaborator OTHER

  • Siriraj Hospital

    collaborator OTHER

  • Ouiheng International Healthcare Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Bannakij Lojanapiwat, MD · Division of Urology, Department of Surgery, Chiangmai University, Thailand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-10-31
Completion
2008-02-29

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01329042 on ClinicalTrials.gov